What are the characteristics of INVENTIVA stock?

INVENTIVA is a company operating in the Santé · Biotechnologies · Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Paris under ISIN FR0013233012.

What is the recent price evolution of INVENTIVA stock?

Since last close: -2.33 %. Over one week: -9.71 %. Over one year: 45.06 %.

Inventiva Announces Temporary Suspension of Its Stock Market Listing Ahead of a Financing Operation

The biopharmaceutical laboratory Inventiva has requested a temporary halt of its stock trading on Euronext Paris on Tuesday morning, ahead of a financing operation, the details of which will be communicated in an upcoming message.

Published on Jun 02, 2026 at 10:25

INVENTIVA

4.19 € -2.33 %

A Defined Suspension Before a Financial Announcement

The suspension on the regulated market of Euronext Paris took effect from 9:00 AM CEST on Tuesday. Trading is expected to resume around 3:30 PM CEST, coinciding with the opening of trading in US dollars on the Nasdaq (9:30 AM ET), where the company is also listed under the same ticker 'IVA'. Inventiva has not specified the nature of the financing operation that led to this suspension. Detailed communication about this transaction is to occur as soon as possible, according to the company.

A Laboratory Focused on the Treatment of Steatohepatitis

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

Inventiva is a clinical-stage biotech specializing in the development of oral small molecules to treat steatohepatitis associated with metabolic dysfunction (MASH). The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the phase 3 NATiV3 clinical trial aimed at adult patients suffering from this common, progressive chronic liver disease.

🏢 Other stocks — Santé

🗞️ Ipsen Stock Under Pressure: Weekly Decline of 6.8% and Threatened Supports 🗞️ Advicenne's Stock Soars Over 55% in a Week Following Approval of Likozam 🗞️ DBV Technologies Breaks Key Support Ahead of Its General Meeting 🗞️ Emeis Stock Falls Below Its Moving Average and Approaches a Technical Support

Context

Period

Period: 1T2026

Key reported figures

Revenue: 0€

Risks mentioned

Aucune garantie que les bons de souscription seront exercés en totalité.
Inventiva a un historique d'exploitation limité et a subi des pertes importantes.

Opportunities identified

Estime que sa trésorerie lui permettra de financer ses activités jusqu'à la mi-premier trimestre 2027.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

A Defined Suspension Before a Financial Announcement

A Laboratory Focused on the Treatment of Steatohepatitis

Context

Also read